

Freedom of Information Request: Our Reference CTMUHB_237_23

You asked:

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Filgotinib**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ozanimod**
- **Tofacitinib**
- **Upadacitinib**
- **Ustekinumab**
- **Vedolizumab**
- **Vedolizumab Injections ONLY (pre-filled pens or syringes)**

Please see response provided in the table below, populated with the data that Medicines Management are able to provide. The period relates to the last 3 months available, which is 1 March 2023 to 31 May 2023.

Medicine	Number of Patients
Adalimumab - Humira	7
Adalimumab Biosimilar	159
Filgotinib	**
Golimumab	0
Infliximab - Remicade	**
Infliximab Biosimilar	219
Ozanimod	**
Tofacitinib	6
Upadacitinib	5
Ustekinumab	126
Vedolizumab	175
Vedolizumab Injections ONLY (pre-filled pens or syringes)	19

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The

data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q2. Does your Health Board participate in clinical trials for the treatment of Ulcerative Colitis? If so, please provide the total number of patients taking part in any Ulcerative Colitis study.

We can confirm that the Health Board does not currently have any clinical trials for the treatment of Ulcerative Colitis open.